Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry


Collaborative Groups: EUMDS Registry Participants)

Disclosures: PF: Research funding and honoraria of Celgene, Janssen, Novartis, Roche, Amgen, and Astex; ASY: honoraria and consultancy for Amgen, Celgene/GenesisPharma, Janssen-Cilag, Gilead, Pfizer, MSD, Novartis, and Genzyme/Sanoﬁ; EHL: research funding Celgene; GS: honoraria and research funding from Celgene, Novartis, Amgen, advisory committee for Amgen, Boehringer-Ingelheim, Celgene, MSD, and Novartis; MSH: research funding Celgene; AMA: consultancy for Novartis, Celgene, and Servier, honoraria from Bristol Meyer Squibb and Alexion; UG: research funding and honorarium from Novartis; RI: research funding from Oncoethix (now Merck MSD), honoraria from Celgene, Sanofi, Novartis, Amgen, and BMS; CvM: funded by the EUMDS project budget; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen Cilag; TdW: honorarium Novartis as project coordinator EUMDS. The remaining authors (MH, GY, SL, SC, LdS, JC, RS, MM, KM, LM, AT, ASA, NGS, DC, AGB, BS, AvdL, JD, MvK, DB, and AS) declare no competing financial interests.